Literature DB >> 22679007

Modern age pathology of pulmonary arterial hypertension.

Elvira Stacher1, Brian B Graham, James M Hunt, Aneta Gandjeva, Steve D Groshong, Vallerie V McLaughlin, Marsha Jessup, William E Grizzle, Michaela A Aldred, Carlyne D Cool, Rubin M Tuder.   

Abstract

RATIONALE: The impact of modern treatments of pulmonary arterial hypertension (PAH) on pulmonary vascular pathology remains unknown.
OBJECTIVES: To assess the spectrum of pulmonary vascular remodeling in the modern era of PAH medication.
METHODS: Assessment of pulmonary vascular remodeling and inflammation in 62 PAH and 28 control explanted lungs systematically sampled.
MEASUREMENTS AND MAIN RESULTS: Intima and intima plus media fractional thicknesses of pulmonary arteries were increased in the PAH group versus the control lungs and correlated with pulmonary hemodynamic measurements. Despite a high variability of morphological measurements within a given PAH lung and among all PAH lungs, distinct pathological subphenotypes were detected in cohorts of PAH lungs. These included a subset of lungs lacking intima or, most prominently, media remodeling, which had similar numbers of profiles of plexiform lesions as those in lungs with more pronounced remodeling. Marked perivascular inflammation was present in a high number of PAH lungs and correlated with intima plus media remodeling. The number of profiles of plexiform lesions was significantly lower in lungs of male patients and those never treated with prostacyclin or its analogs.
CONCLUSIONS: Our results indicate that multiple features of pulmonary vascular remodeling are present in patients treated with modern PAH therapies. Perivascular inflammation may have an important role in the processes of vascular remodeling, all of which may ultimately lead to increased pulmonary artery pressure. Moreover, our study provides a framework to interpret and design translational studies in PAH.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22679007      PMCID: PMC3886716          DOI: 10.1164/rccm.201201-0164OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  21 in total

Review 1.  Treatment of pulmonary arterial hypertension.

Authors:  Marc Humbert; Olivier Sitbon; Gérald Simonneau
Journal:  N Engl J Med       Date:  2004-09-30       Impact factor: 91.245

2.  The histopathology of 36 cases of plexogenic pulmonary arteriopathy.

Authors:  A W Caslin; D Heath; B Madden; M Yacoub; J R Gosney; P Smith
Journal:  Histopathology       Date:  1990-01       Impact factor: 5.087

3.  Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension.

Authors:  R M Tuder; B Groves; D B Badesch; N F Voelkel
Journal:  Am J Pathol       Date:  1994-02       Impact factor: 4.307

4.  Pulmonary changes in congenital heart disease with Down's syndrome: their significance as a cause of postoperative respiratory failure.

Authors:  S Yamaki; T Horiuchi; T Takahashi
Journal:  Thorax       Date:  1985-05       Impact factor: 9.139

5.  Histopathology of primary pulmonary hypertension. A qualitative and quantitative study of pulmonary blood vessels from 58 patients in the National Heart, Lung, and Blood Institute, Primary Pulmonary Hypertension Registry.

Authors:  G G Pietra; W D Edwards; J M Kay; S Rich; J Kernis; B Schloo; S M Ayres; E H Bergofsky; B H Brundage; K M Detre
Journal:  Circulation       Date:  1989-11       Impact factor: 29.690

6.  Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor.

Authors:  Carl Atkinson; Susan Stewart; Paul D Upton; Rajiv Machado; Jennifer R Thomson; Richard C Trembath; Nicholas W Morrell
Journal:  Circulation       Date:  2002-04-09       Impact factor: 29.690

7.  Lung biopsy specimens in the evaluation of pulmonary vascular disease.

Authors:  C A Wagenvoort
Journal:  Chest       Date:  1980-05       Impact factor: 9.410

8.  Survival in patients with primary pulmonary hypertension. Results from a national prospective registry.

Authors:  G E D'Alonzo; R J Barst; S M Ayres; E H Bergofsky; B H Brundage; K M Detre; A P Fishman; R M Goldring; B M Groves; J T Kernis
Journal:  Ann Intern Med       Date:  1991-09-01       Impact factor: 25.391

9.  Lung biopsy in congenital heart disease: a morphometric approach to pulmonary vascular disease.

Authors:  M Rabinovitch; S G Haworth; A R Castaneda; A S Nadas; L M Reid
Journal:  Circulation       Date:  1978-12       Impact factor: 29.690

10.  Primary pulmonary hypertension: a histopathologic study of 80 cases.

Authors:  J Bjornsson; W D Edwards
Journal:  Mayo Clin Proc       Date:  1985-01       Impact factor: 7.616

View more
  220 in total

1.  Oestrogen inhibition reverses pulmonary arterial hypertension and associated metabolic defects.

Authors:  Xinping Chen; Eric D Austin; Megha Talati; Joshua P Fessel; Eric H Farber-Eger; Evan L Brittain; Anna R Hemnes; James E Loyd; James West
Journal:  Eur Respir J       Date:  2017-08-03       Impact factor: 16.671

Review 2.  Redox biology in pulmonary arterial hypertension (2013 Grover Conference Series).

Authors:  Joshua P Fessel; James D West
Journal:  Pulm Circ       Date:  2015-12       Impact factor: 3.017

Review 3.  Discovery of a murine model of clinical PAH: Mission impossible?

Authors:  Zhiyu Dai; You-Yang Zhao
Journal:  Trends Cardiovasc Med       Date:  2016-12-15       Impact factor: 6.677

4.  Meta-analysis of blood genome-wide expression profiling studies in pulmonary arterial hypertension.

Authors:  Jason M Elinoff; Adrien J Mazer; Rongman Cai; Mengyun Lu; Grace Graninger; Bonnie Harper; Gabriela A Ferreyra; Junfeng Sun; Michael A Solomon; Robert L Danner
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2019-10-16       Impact factor: 5.464

5.  Codependence of Bone Morphogenetic Protein Receptor 2 and Transforming Growth Factor-β in Elastic Fiber Assembly and Its Perturbation in Pulmonary Arterial Hypertension.

Authors:  Nancy F Tojais; Aiqin Cao; Ying-Ju Lai; Lingli Wang; Pin-I Chen; Miguel A Alejandre Alcazar; Vinicio A de Jesus Perez; Rachel K Hopper; Christopher J Rhodes; Matthew A Bill; Lynn Y Sakai; Marlene Rabinovitch
Journal:  Arterioscler Thromb Vasc Biol       Date:  2017-06-15       Impact factor: 8.311

6.  Diverse forms of pulmonary hypertension remodel the arterial tree to a high shear phenotype.

Authors:  Roblee P Allen; Edward S Schelegle; Stephen H Bennett
Journal:  Am J Physiol Heart Circ Physiol       Date:  2014-05-23       Impact factor: 4.733

7.  Toll-like Receptor 3 Is a Therapeutic Target for Pulmonary Hypertension.

Authors:  Daniela Farkas; A A Roger Thompson; Aneel R Bhagwani; Schuyler Hultman; Hyun Ji; Naveen Kotha; Grant Farr; Nadine D Arnold; Adam Braithwaite; Helen Casbolt; Jennifer E Cole; Ian Sabroe; Claudia Monaco; Carlyne D Cool; Elena A Goncharova; Allan Lawrie; Laszlo Farkas
Journal:  Am J Respir Crit Care Med       Date:  2019-01-15       Impact factor: 21.405

8.  NPY/Y₁ receptor-mediated vasoconstrictory and proliferative effects in pulmonary hypertension.

Authors:  S Crnkovic; B Egemnazarov; P Jain; U Seay; N Gattinger; L M Marsh; Z Bálint; G Kovacs; B Ghanim; W Klepetko; R T Schermuly; N Weissmann; A Olschewski; G Kwapiszewska
Journal:  Br J Pharmacol       Date:  2014-08       Impact factor: 8.739

9.  Carfilzomib reverses pulmonary arterial hypertension.

Authors:  Xinhong Wang; Yasmine F Ibrahim; Dividutta Das; Makhosazane Zungu-Edmondson; Nataliia V Shults; Yuichiro J Suzuki
Journal:  Cardiovasc Res       Date:  2016-03-06       Impact factor: 10.787

10.  Mineralocorticoid receptor antagonism attenuates experimental pulmonary hypertension.

Authors:  Ioana R Preston; Kristen D Sagliani; Rod R Warburton; Nicholas S Hill; Barry L Fanburg; Iris Z Jaffe
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2013-03-01       Impact factor: 5.464

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.